Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05GlobeNewsWire • 11/02/25
Alvotech Announces Changes in Global Business Development and Commercial Operations TeamGlobeNewsWire • 10/22/25
Wall Street Analysts See a 105.88% Upside in Alvotech (ALVO): Can the Stock Really Move This High?Zacks Investment Research • 10/15/25
European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines AgencyGlobeNewsWire • 10/06/25
Alvotech (ALVO) Surges 8.6%: Is This an Indication of Further Gains?Zacks Investment Research • 09/24/25
Alvotech vs. Teva Pharma: Which Generic Drugmaker is the Better Play?Zacks Investment Research • 09/23/25
European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech's Proposed Biosimilar to Prolia® and Xgeva®GlobeNewsWire • 09/22/25
European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech's Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization PartnerGlobeNewsWire • 09/22/25
Here's How ALVO's Commercial Partnerships Are Driving Top-line GrowthZacks Investment Research • 09/18/25
Alvotech (ALVO) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/10/25
ALVO Stock Trades Near 52-Week Low: Should You Buy, Hold or Sell?Zacks Investment Research • 09/09/25
Alvotech Meets Investors and Participates in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New YorkGlobeNewsWire • 09/04/25
Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea®GlobeNewsWire • 08/21/25
Alvotech Reports Results for the First Six Months of 2025 and Provides a Business UpdateGlobeNewsWire • 08/13/25
Alvotech Reports Results for the First Six Months of 2025 and Provides a Business UpdateGlobeNewsWire • 08/13/25
Wall Street Analysts Think Alvotech (ALVO) Could Surge 102.31%: Read This Before Placing a BetZacks Investment Research • 08/13/25
Alvotech Announces Webcast to Report Financial Results for the First Half of 2025 on August 14, 2025, at 8:00 am EDTGlobeNewsWire • 08/06/25